Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 9-ing-41
2. 1034895-42-5
3. Elraglusib
4. Elraglusib [usan]
5. Nd1sof0dlu
6. Chembl483465
7. 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
8. 1h-pyrrole-2,5-dione, 3-(5-fluoro-3-benzofuranyl)-4-(5-methyl-5h-1,3-dioxolo(4,5-f)indol-7-yl)-
9. 3-(5-fluoro-benzofuran-3-yl)-4-(5-methyl-5h-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
10. Unii-nd1sof0dlu
11. Elraglusib [inn]
12. Schembl3152351
13. Gtpl11412
14. 9-ing-41 [who-dd]
15. Ex-a4074
16. Bdbm50267716
17. S9602
18. Who 11553
19. Sb19735
20. Compound 26 [pmid: 19338355]
21. Hy-113914
22. Cs-0063319
23. E73486
24. 3-(5-fluoro-1-benzofuran-3-yl)-4-(5-methyl-5h- (1,3)dioxolo(4,5-f)indol-7-yl)-1h-pyrrole-2,5-dione
25. 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
26. 4-(5-methyl-5h-[1,3]dioxolo[4,5-f]-indol-7-yl)-3-(5-fluoro-1-benzofuran-3-yl)-1 H-pyrrole-2,5-dione
| Molecular Weight | 404.3 g/mol |
|---|---|
| Molecular Formula | C22H13FN2O5 |
| XLogP3 | 3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 2 |
| Exact Mass | 404.08084968 g/mol |
| Monoisotopic Mass | 404.08084968 g/mol |
| Topological Polar Surface Area | 82.7 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 802 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Elraglusib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Elraglusib, including repackagers and relabelers. The FDA regulates Elraglusib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Elraglusib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Elraglusib supplier is an individual or a company that provides Elraglusib active pharmaceutical ingredient (API) or Elraglusib finished formulations upon request. The Elraglusib suppliers may include Elraglusib API manufacturers, exporters, distributors and traders.
Elraglusib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Elraglusib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Elraglusib GMP manufacturer or Elraglusib GMP API supplier for your needs.
A Elraglusib CoA (Certificate of Analysis) is a formal document that attests to Elraglusib's compliance with Elraglusib specifications and serves as a tool for batch-level quality control.
Elraglusib CoA mostly includes findings from lab analyses of a specific batch. For each Elraglusib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Elraglusib may be tested according to a variety of international standards, such as European Pharmacopoeia (Elraglusib EP), Elraglusib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Elraglusib USP).
LOOKING FOR A SUPPLIER?
